Related by context. Frequent words. (Click for all words.) 63 Inc Therapeutic Competitors 62 Presents Positive 60 Nasdaq BIIB 60 Completes Enrollment 59 Skymark Research Initiates Independent 58 Idera Pharmaceuticals 58 Report Initiates Independent 58 Named Cool Vendor 57 Q2 Loss Narrows 57 Calls Purchased 57 Co. Initiates Independent 56 Trubion Pharmaceuticals 56 Q3 Loss Narrows 56 Guides FY# Quick Facts 56 AUXL 56 DVAX 56 Detects Unusual Activity 56 INCY 56 Q1 Loss Narrows 56 TheFortuneFinancial.com Free Market 56 Bearish Pressure Building 56 Exploit collaboration 56 Detailed Product 56 Q3 Loss Widens 55 PROFILE CO 55 Q4 Loss Narrows 55 BMRN 55 Guides Below 55 QLTI 55 RELEASES ITS QUARTERLY NUMBERS 55 Q2 Loss Widens 55 Bearish Harami Pattern 55 Merrimack Pharmaceuticals 55 Ironwood Pharmaceuticals Inc. 55 Bullish Engulfing Pattern 55 Bullish Harami Pattern 55 Q4 Loss Widens 55 % SELL OFF 55 Drug Candidate 54 Peter Antipatis 54 QGEN 54 Posts Large Volume 54 CEO Exercises Options 54 Schedules Fiscal 54 Hybridon 54 Cloud Cover Pattern 54 Coley Pharmaceutical Group 54 Archemix Corp. 54 SMARTREND 'S OPTION SCANNER 54 SHARES COULD POTENTIALLY PULLBACK 54 THE TREND CONTINUES LOWER 54 Noteworthy Trading 54 AVEO Pharmaceuticals Inc. 54 quotes/comstock/# * 54 EnVivo Pharmaceuticals 54 Inotek 54 Options Trader Alert 54 VOLUME WATCH FOR 54 SEE CONTINUED UPWARD MOMENTUM 53 CRXX 53 Announces Presentation 53 Q2 Profit Surges 53 Interesting Options Volume 53 Stock Upgraded 53 REACHES INITIAL SUPPORT LEVEL 53 UPWARD MOMENTUM LOOKS TO 53 Stock Downgraded 53 Bearish Engulfing Pattern 53 Small Molecules 53 Guides Above 53 RELATIVELY GOOD PERFORMANCE DETECTED 53 ENZN 53 IMGN 53 BULLISH MOVING AVERAGE CROSSOVER 53 IDIX 53 WATCH FOR CONTINUED GAINS 53 SET TO POSSIBLY PULLBACK 53 RELEASES ITS QUARTERLY EARNINGS 53 Repligen Corporation 53 Alnylam Pharmaceuticals 53 Secures Additional 53 SMARTREND RESEARCH REPORT AVAILABLE 53 Altus Pharmaceuticals 53 REACHES INITIAL RESISTANCE LEVEL 53 Rigel Pharmaceuticals 53 DOWNWARD MOMENTUM LOOKS TO 53 Finalizes Acquisition 53 #.#X ABOVE AVERAGE VOLUME 53 Preclinical Data 53 Sofinnova Ventures 53 SGX Pharmaceuticals 53 SHARES COULD PULLBACK 53 FDA Accepts 53 Lexicon Genetics 53 CMVT.PK 53 SGMO 53 Enzon Pharmaceuticals 53 OSIR 53 Analysts Begin Coverage 52 Infinity Pharmaceuticals 52 Q1 Loss Widens